Related coverage linked through entity extraction aliases.
Aug 15, 2026
Valneva withdrew its U.S. BLA and IND for chikungunya vaccine Ixchiq after an FDA clinical hold tied to a serious adverse event. The company reported a wider FY2025 net loss of €115.2 million, while its Lyme vaccine VLA15 showed over 70% efficacy in Phase III.
May 08, 2026
Recent studies highlight progress in monoclonal antibodies against measles, Lyme disease, and Epstein-Barr virus. A Phase I Lyme antibody trial showed lasting protection, while preclinical antibodies blocked EBV and measles infection.
Jul 01, 2026
Two new studies advance Lyme disease research: anti-lipid antibodies may enable earlier diagnosis and detect persistent symptoms, while cell wall changes in Borrelia burgdorferi offer insights into Lyme arthritis pathogenesis and potential treatment targets.
Apr 23, 2026
January and March 2026 drug pipeline updates included Phase 3 results, Fast Track designations and Priority Review decisions across multiple disease areas. Mavacamten, teplizumab-mzwv, anifrolumab, AXS-05, gedatolisib and AFTX-201 were among the programs with notable milestones.
Apr 20, 2026
Pfizer and Valneva said their investigational Lyme disease vaccine candidate showed more than 70% efficacy in the phase 3 VALOR trial. Pfizer plans regulatory submissions after the study, which reported no safety concerns at the time of analysis.
Apr 04, 2026
Pfizer and Valneva said their investigational Lyme disease vaccine showed more than 70% efficacy in the Phase 3 VALOR trial with a favorable safety profile. The companies plan regulatory submissions despite the trial missing its primary statistical criterion due to fewer Lyme cases than expected.
Feb 15, 2026
The FDA agreed to review Moderna's mRNA flu vaccine application after initially rejecting it, reversing course within a week. The agency will now consider full approval for adults 50-64 and accelerated approval for those 65 and above, with a decision expected by August 5.
